Literature DB >> 20021448

Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine.

P T Francis1.   

Abstract

Behavioural symptoms are a significant problem in Alzheimer's disease (AD). Symptoms including agitation/aggression and psychosis reduce patient quality of life, significantly increase caregiver burden, and often trigger nursing home placement. Underlying changes in the serotonergic, noradrenergic and cholinergic systems have been linked to some behavioural problems, however, the use of antipsychotics in this population has been associated with significant safety concerns. A role for the glutamate system in schizophrenia, as well as in anxiety and depression, has been suggested, and evidence is emerging for a role for dysfunctional glutamate neurotransmission (via N-methyl-D-aspartate (NMDA) receptors) in certain behavioural changes in dementia. For example, the NMDA receptor antagonist, memantine has been shown to improve cognition, function (activities of daily living, ADLs) and, more recently, agitation/aggression, and delusions in AD patients. To date, little information is available regarding the neurochemical basis of agitation/aggression. However, the frontal and cingulate cortices--specifically, the formation of neurofibrillary tangles in glutamatergic pyramidal neurones of these areas--are proposed as regional substrates of these behaviours. Given that memantine displays a favourable tolerability profile, it is relevant to investigate the underlying mechanism linking memantine with the behavioural elements of AD. One hypothesis proposes that memantine corrects dysfunctional glutamatergic neurotransmission in the frontal and cingulate cortices, thereby normalising pathways responsible for causing agitation. An alternative hypothesis is based on the observation that increased tangle formation is associated with agitation, and on recent studies where memantine has been shown to reduce tau phosphorylation via glycogen synthase kinase (GSK)-3 or activation of protein phosphatase (PP)-2A, which might subsequently lead to reduced agitation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20021448     DOI: 10.2174/1874467210902010077

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  15 in total

Review 1.  NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders.

Authors:  Charles F Zorumski; Yukitoshi Izumi
Journal:  Neurosci Biobehav Rev       Date:  2012-01-02       Impact factor: 8.989

2.  Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.

Authors:  Taro Kishi; Yuki Matsuda; Nakao Iwata
Journal:  Psychopharmacology (Berl)       Date:  2017-05-15       Impact factor: 4.530

3.  Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity.

Authors:  Dayong Wang; G Govindaiah; Ruijie Liu; Vania De Arcangelis; Charles L Cox; Yang K Xiang
Journal:  FASEB J       Date:  2010-04-15       Impact factor: 5.191

Review 4.  Emotion Processing Dysfunction in Alzheimer's Disease: An Overview of Behavioral Findings, Systems Neural Correlates, and Underlying Neural Biology.

Authors:  Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li
Journal:  Am J Alzheimers Dis Other Demen       Date:  2022 Jan-Dec       Impact factor: 2.632

5.  Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease.

Authors:  Daniela L Krause; Norbert Müller
Journal:  Int J Alzheimers Dis       Date:  2010-06-14

6.  Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.

Authors:  Nirmal Sonali; Manjari Tripathi; Rajesh Sagar; Thirumurthy Velpandian; Vivekanandhan Subbiah
Journal:  CNS Neurosci Ther       Date:  2012-12-04       Impact factor: 5.243

7.  Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge.

Authors:  Marie Lou Camara; Frances Corrigan; Emily J Jaehne; Magdalene C Jawahar; Helen Anscomb; Bernhard T Baune
Journal:  Neuropsychopharmacology       Date:  2014-08-08       Impact factor: 7.853

8.  NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.

Authors:  Yu-Jhen Huang; Chieh-Hsin Lin; Hsien-Yuan Lane; Guochuan E Tsai
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

9.  Exendin-4 protected against cognitive dysfunction in hyperglycemic mice receiving an intrahippocampal lipopolysaccharide injection.

Authors:  Hei-Jen Huang; Yen-Hsu Chen; Keng-Chen Liang; Yu-Syuan Jheng; Jhih-Jhen Jhao; Ming-Tsan Su; Guey-Jen Lee-Chen; Hsiu Mei Hsieh-Li
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

10.  Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial.

Authors:  Chris Fox; Monica Crugel; Ian Maidment; Bjorn Henrik Auestad; Simon Coulton; Adrian Treloar; Clive Ballard; Malaz Boustani; Cornelius Katona; Gill Livingston
Journal:  PLoS One       Date:  2012-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.